New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact

References

• Wang L, Lu B, He M, et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. [2022 Feb 16];10:811044. doi: 10.3389/fpubh.2022.811044
   PubMed Web of Science ®Google Scholar
• Ng K, Smith S, Shamash J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncol Ther. 2020 Dec;8(2):209–230. doi: 10.1007/s40487-020-00119-z
   PubMed Web of Science ®Google Scholar
• Choi E, Buie J, Camacho J, et al. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, Clinicians and medical providers. Res Rep Urol. [2022 Mar 30];14:87–108. doi: 10.2147/RRU.S303215
   PubMed Web of Science ®Google Scholar
• Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. [2013 Dec 5];32(49):5501–5511. doi: 10.1038/onc.2013.206
   PubMed Web of Science ®Google Scholar
• Chang C, Saltzman A, Yeh S, et al. Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr. 1995;5(2):97–125. doi: 10.1615/CritRevEukarGeneExpr.v5.i2.10
   PubMed Web of Science ®Google Scholar
• Fujita K, Nonomura N. Role of androgen receptor in prostate cancer: a review. World J Mens Health. 2019 Sep;37(3):288–295. doi: 10.5534/wjmh.180040
   PubMedGoogle Scholar
• Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. [2023 Sep 10];41(26):4267–4278. doi: 10.1200/JCO.23.00433
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. [2018 Apr 10];36(11):1080–1087. doi: 10.1200/JCO.2017.75.3657
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. [2016 Mar 19];387(10024):1163–1177. doi: 10.1016/S0140-6736(15)01037-5
   PubMed Web of Science ®Google Scholar
• Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Feb;14(2):149–158. doi: 10.1016/S1470-2045(12)70560-0
   PubMed Web of Science ®Google Scholar
• Jacob A, Raj R, Allison DB, et al. Androgen receptor signaling in prostate cancer and therapeutic strategies. Cancers (Basel). [2021 Oct 28];13(21):5417. doi: 10.3390/cancers13215417
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. COU-AA-301 investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. [2011 May 26];364(21):1995–2005. doi: 10.1056/NEJMoa1014618.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. AFFIRM investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. [2012 Sep 27];367(13):1187–1197. doi: 10.1056/NEJMoa1207506.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. COU-AA-302 investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152–160. doi: 10.1016/S1470-2045(14)71205-7
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. PREVAIL investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. [2014 Jul 31];371(5):424–433. doi: 10.1056/NEJMoa1405095
   PubMed Web of Science ®Google Scholar
• Berruti A, Bracarda S, Caffo O, et al. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives. Cancer Treat Rev. 2023 Apr;115:102525. doi: 10.1016/j.ctrv.2023.102525
   PubMed Web of Science ®Google Scholar
• Jarman M, Barrie SE, Llera JM. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem. [1998 Dec 31];41(27):5375–5381. doi: 10.1021/jm981017j
   PubMed Web of Science ®Google Scholar
• O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. [2004 Jun 14];90(12):2317–2325. doi: 10.1038/sj.bjc.6601879.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. [2010 Mar 20];28(9):1481–1488. doi: 10.1200/JCO.2009.24.1281
   PubMed Web of Science ®Google Scholar
• Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 2011 May;125(1–2):23–31. doi: 10.1016/j.jsbmb.2010.11.005
   PubMed Web of Science ®Google Scholar
• Auchus RJ, Yu MK, Nguyen S, et al. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncology. 2014 Dec;19(12):1231–1240. doi: 10.1634/theoncologist.2014-0167
   Google Scholar
• Groenland SL, van Nuland M, Bergman AM, et al; Dutch Pharmacology Oncology Group (DPOG). Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. Eur J Cancer. 2020 May;130:32–38. doi: 10.1016/j.ejca.2020.02.012
   PubMed Web of Science ®Google Scholar
• Danielak D, Krejčí T, Beránek J. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. Eur J Pharm Sci. [2022 Sep 1];176:106254. doi: 10.1016/j.ejps.2022.106254
   PubMed Web of Science ®Google Scholar
• Marbury T, Lawitz E, Stonerock R, et al. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. J Clin Pharmacol. 2014 Jul;54(7):732–741. doi: 10.1002/jcph.253
   PubMed Web of Science ®Google Scholar
• Bouhajib M, Tayab Z. Evaluation of the pharmacokinetics of abiraterone acetate and abiraterone following single-dose administration of abiraterone acetate to healthy subjects. Clin Drug Investig. 2019 Mar;39(3):309–317. doi: 10.1007/s40261-019-00752-1
   PubMed Web of Science ®Google Scholar
• Chi KN, Spratlin J, Kollmannsberger C, et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol. 2015 Dec;55(12):1406–1414. doi: 10.1002/jcph.564
   PubMed Web of Science ®Google Scholar
• Basa-Dénes O, Solymosi T, Ötvös Z, et al. Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate. Eur J Pharm Sci. [2019 Mar 1];129:79–86. doi: 10.1016/j.ejps.2019.01.001
   PubMed Web of Science ®Google Scholar
• Sakai Y, Fukami T, Nagaoka M, et al. Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans. Life Sci. [2021 Nov 1];284:119896. doi: 10.1016/j.lfs.2021.119896
   PubMed Web of Science ®Google Scholar
• Geboers S, Stappaerts J, Mols R, et al. The effect of food on the intraluminal behavior of abiraterone acetate in man. J Pharm Sci. 2016 Sep;105(9):2974–2981. doi: 10.1016/j.xphs.2016.03.008
   PubMed Web of Science ®Google Scholar
• Acharya M, Gonzalez M, Mannens G, et al. A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Xenobiotica. 2013 Apr;43(4):379–389. doi: 10.3109/00498254.2012.721022
   PubMed Web of Science ®Google Scholar
• Van Speybroeck M, Mellaerts R, Mols R, et al. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur J Pharm Sci. [2010 Dec 23];41(5):623–630. doi: 10.1016/j.ejps.2010.09.002
   PubMed Web of Science ®Google Scholar
• Carton E, Noe G, Huillard O, et al. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer. 2017 Feb;72:54–61. doi: 10.1016/j.ejca.2016.11.027
   PubMed Web of Science ®Google Scholar
• van Nuland M, Groenland SL, Bergman AM, et al. Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 Jun;23(2):244–251. doi: 10.1038/s41391-019-0179-5
   PubMed Web of Science ®Google Scholar
• Mueller-Schoell A, Groenland SL, Scherf-Clavel O, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021 Apr;77(4):441–464. doi: 10.1007/s00228-020-03014-8
   PubMed Web of Science ®Google Scholar
• Li Z, Bishop AC, Alyamani M, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. [2015 Jul 16];523(7560):347–351. doi: 10.1038/nature14406
   PubMed Web of Science ®Google Scholar
• Blanchet B, Carton E, Alyamani M, et al. A PK/PD study of delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. Pharmacol Res. 2018 Oct;136:56–61. doi: 10.1016/j.phrs.2018.08.016
   PubMed Web of Science ®Google Scholar
• Crombag MBS, van Nuland M, Bergman AM, et al. Impact of age on exposure to oral antiandrogen therapies in clinical practice. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):168–175. doi: 10.1038/s41391-018-0096-z
   PubMed Web of Science ®Google Scholar
• Stuyckens K, Saad F, Xu XS, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014 Dec;53(12):1149–1160. doi: 10.1007/s40262-014-0178-6
   PubMed Web of Science ®Google Scholar
• Jung ME, Ouk S, Yoo D, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem. [2010 Apr 8];53(7):2779–2796. doi: 10.1021/jm901488g
   PubMed Web of Science ®Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. [2012 Mar 15];72(6):1494–1503. doi: 10.1158/0008-5472.CAN-11-3948
   PubMed Web of Science ®Google Scholar
• de Vries R, Jacobs F, Mannens G, et al. Apalutamide absorption, metabolism, And excretion in healthy men, and enzyme reaction in human hepatocytes. Drug Metab Dispos. 2019 May;47(5):453–464. doi: 10.1124/dmd.118.084517
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. [2013 Oct 1];31(28):3525–3530. doi: 10.1200/JCO.2013.50.1684
   PubMed Web of Science ®Google Scholar
• Yu A, Erba M, Hazra A. Pharmacokinetics and use-testing of apalutamide prepared in aqueous food vehicles for alternative administration. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1375–1384. doi: 10.1002/cpdd.1001
   PubMed Web of Science ®Google Scholar
• Duran I, Carles J, Bulat I, et al. Pharmacokinetic drug-drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer. Clin Pharmacokinet. 2020 Sep;59(9):1135–1148. doi: 10.1007/s40262-020-00882-2
   PubMed Web of Science ®Google Scholar
• Pérez-Ruixo C, Pérez-Blanco JS, Chien C, et al. Population pharmacokinetics of apalutamide and its active metabolite N-Desmethyl-apalutamide in healthy and castration-resistant prostate cancer subjects. Clin Pharmacokinet. 2020 Feb;59(2):229–244. doi: 10.1007/s40262-019-00808-7
   PubMed Web of Science ®Google Scholar
• Van den Bergh A, Snoeys J, De Zwart L, et al. Pharmacokinetic drug-drug interaction of apalutamide, part 2: investigating interaction potential using a physiologically based pharmacokinetic model. Clin Pharmacokinet. 2020 Sep;59(9):1149–1160. doi: 10.1007/s40262-020-00881-3.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. SPARTAN investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. [2018 Apr 12];378(15):1408–1418. doi: 10.1056/NEJMoa1715546
   PubMed Web of Science ®Google Scholar
• Gibbons JA, Ouatas T, Krauwinkel W, et al. Clinical pharmacokinetic studies of enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1043–1055. doi: 10.1007/s40262-015-0271-5.
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. [2009 May 8];324(5928):787–790. doi: 10.1126/science.1168175
   PubMed Web of Science ®Google Scholar
• Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. [2015 Aug 8];3(2):64–76.
   PubMedGoogle Scholar
• Bennett D, Gibbons JA, Mol R, et al. Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC-MS/MS. Bioanalysis. 2014 Mar;6(6):737–744. doi: 10.4155/bio.13.325
   PubMed Web of Science ®Google Scholar
• van Nuland M, Bergman AM, Rosing H, et al. Exposure-response assessment of enzalutamide and its major metabolites in a real-world cohort of patients with metastatic castration-resistant prostate cancer. Pharmacotherapy. 2019 Dec;39(12):1137–1145. doi: 10.1002/phar.2339
   PubMed Web of Science ®Google Scholar
• Joulia ML, Carton E, Jouinot A, et al. Pharmacokinetic/Pharmacodynamic relationship of enzalutamide and its active metabolite N-Desmethyl enzalutamide in metastatic castration-resistant prostate cancer patients. Clin Genitourin Cancer. 2020 Apr;18(2):155–160. doi: 10.1016/j.clgc.2019.05.020
   PubMed Web of Science ®Google Scholar
• Benoist GE, Hendriks RJ, Mulders PF, et al. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016 Nov;55(11):1369–1380. doi: 10.1007/s40262-016-0403-6
   PubMed Web of Science ®Google Scholar
• Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. [2015 Jul 3];5(1):12007. doi: 10.1038/srep12007
   PubMedGoogle Scholar
• Fizazi K, Massard C, Bono P, et al. ARADES study group. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014 Aug;15(9):975–985. doi: 10.1016/S1470-2045(14)70240-2
   PubMed Web of Science ®Google Scholar
• Taavitsainen P, Gieschen H, Korjamo T, et al. Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats. Xenobiotica. 2020 Aug;50(8):967–979. doi: 10.1080/00498254.2020.1723038
   PubMed Web of Science ®Google Scholar
• Nykänen P, Korjamo T, Gieschen H, et al. Pharmacokinetics of darolutamide, its diastereomers and active metabolite in the mouse: response to Saini NK et al. Drug Metab Lett. 2021;14(1):9–16. doi: 10.2174/1872312814666201112121129
   PubMedGoogle Scholar
• Sugawara T, Baumgart SJ, Nevedomskaya E, et al. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models. Int J Cancer. [2019 Sep 1];145(5):1382–1394. doi: 10.1002/ijc.32242
   PubMed Web of Science ®Google Scholar
• Zurth C, Nykänen P, Wilkinson G, et al. Clinical pharmacokinetics of the androgen receptor inhibitor darolutamide in healthy subjects and patients with hepatic or renal impairment. Clin Pharmacokinet. 2022 Apr;61(4):565–575. doi: 10.1007/s40262-021-01078-y
   PubMed Web of Science ®Google Scholar
• Massard C, Penttinen HM, Vjaters E, et al. Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016 May;69(5):834–840. doi: 10.1016/j.eururo.2015.09.046
   PubMed Web of Science ®Google Scholar
• Matsubara N, Mukai H, Hosono A, et al. Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2017;80(6):1063–1072. doi: 10.1007/s00280-017-3417-3
   PubMed Web of Science ®Google Scholar
• Podgoršek E, Mehra N, van Oort IM, et al. Clinical pharmacokinetics and pharmacodynamics of the next generation androgen receptor inhibitor-darolutamide. Clin Pharmacokinet. 2023 Aug;62(8):1049–1061. doi: 10.1007/s40262-023-01268-w
   PubMed Web of Science ®Google Scholar
• Shore ND. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother. 2017 Jun;18(9):945–952. doi: 10.1080/14656566.2017.1329820
   PubMed Web of Science ®Google Scholar
• Zurth C, Sandmann S, Trummel D, et al. Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography. J Clin Oncol. 2018;36(6_suppl):345. doi: 10.1200/JCO.2018.36.6_suppl.345
   Web of Science ®Google Scholar
• Fizazi K, Albiges L, Loriot Y, et al. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015;15(9):1007–1017. doi: 10.1586/14737140.2015.1081566
   PubMed Web of Science ®Google Scholar
• Zurth C, Koskinen M, Fricke R, et al. Drug-drug interaction potential of Darolutamide: In Vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747–759. doi: 10.1007/s13318-019-00577-5
   PubMed Web of Science ®Google Scholar
• Taavitsainen P, Prien O, Kähkönen M, et al. Metabolism and Mass balance of the novel nonsteroidal androgen receptor inhibitor darolutamide in humans. Drug Metab Dispos. 2021 Jun;49(6):420–433. doi: 10.1124/dmd.120.000309
   PubMed Web of Science ®Google Scholar
• Bögemann M, Facchini G, Bauernhofer T, et al. Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice. Ir J Med Sci. 2023 Dec;192(6):2643–2651. doi: 10.1007/s11845-023-03303-y
   PubMed Web of Science ®Google Scholar
• Tsang ES, de Haan M, Eigl BJ. A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer. J Oncol Pharm Pract. 2018 Mar;24(2):143–145. doi: 10.1177/1078155216689381
   PubMed Web of Science ®Google Scholar
• Krauwinkel W, Noukens J, van Dijk J, et al. Comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects. J Clin Pharm Ther. 2017 Jun;42(3):268–275. doi: 10.1111/jcpt.12503
   PubMed Web of Science ®Google Scholar
• Bernard A, Vaccaro N, Acharya M, et al. Impact on abiraterone pharmacokinetics and safety: open-label drug-drug interaction studies with ketoconazole and rifampicin. Clin Pharmacol Drug Dev. 2015 Jan;4(1):63–73. doi: 10.1002/cpdd.132
   PubMed Web of Science ®Google Scholar
• Chi KN, Tolcher A, Lee P, et al. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013 Jan;71(1):237–244. doi: 10.1007/s00280-012-2001-0
   PubMed Web of Science ®Google Scholar
• Monbaliu J, Gonzalez M, Bernard A, et al. In vitro and in vivo drug-drug interaction studies to assess the effect of abiraterone acetate, abiraterone, and metabolites of abiraterone on CYP2C8 activity. Drug Metab Dispos. 2016 Oct;44(10):1682–1691. doi: 10.1124/dmd.116.070672
   PubMed Web of Science ®Google Scholar
• Boujonnier F, Lemaitre F, Scailteux LM. Pharmacokinetic interactions between abiraterone, apalutamide, darolutamide or enzalutamide and antithrombotic drugs: prediction of clinical events and review of pharmacological information. Cardiovasc Drugs Ther. 2023 May 1. doi: 10.1007/s10557-023-07453-0
   PubMed Web of Science ®Google Scholar
• Lehr T, Staab A, Trommeshauser D, et al. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Clin Pharmacokinet. 2010;49(1):53–66. doi: 10.2165/11317210-000000000-00000
   PubMed Web of Science ®Google Scholar
• Seo KA, Bae SK, Choi YK, et al. Metabolism of 1’- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos. 2010 Nov;38(11):2007–2013. doi: 10.1124/dmd.110.035295
   PubMed Web of Science ®Google Scholar
• Jones DR, Moran JH, Miller GP. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev. 2010 Feb;42(1):55–61. doi: 10.3109/03602530903209395
   PubMed Web of Science ®Google Scholar
• Bellesoeur A, Thomas-Schoemann A, Allard M, et al. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: clinical consequences. Crit Rev Oncol Hematol. 2018 Sep;129:102–112. doi: 10.1016/j.critrevonc.2018.06.015
   PubMed Web of Science ®Google Scholar
• Shore N, Zurth C, Fricke R, et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS Trial. Target Oncol. 2019 Oct;14(5):527–539. doi: 10.1007/s11523-019-00674-0
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Griffen SC, et al. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diab Obes Metab. 2013 Mar;15(3):280–283. doi: 10.1111/dom.12024
   PubMed Web of Science ®Google Scholar
• Konig J, Muller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and efects. Pharmacol Rev. 2013;65(3):944–966. doi: 10.1124/pr.113.007518
   PubMed Web of Science ®Google Scholar
• Buck SAJ, Talebi Z, Drabison T, et al. Darolutamide does not interfere with OATP-mediated uptake of docetaxel. Int J Cancer. [2024 Mar 16]. doi: 10.1002/ijc.34922
   Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. LATITUDE investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. [2017 Jul 27];377(4):352–360. doi: 10.1056/NEJMoa1704174
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 May;20(5):686–700. doi: 10.1016/S1470-2045(19)30082-8
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Spears MR, et al. STAMPEDE investigators. Abiraterone for prostate cancer not Previously treated with hormone therapy. N Engl J Med. [2017 Jul 27];377(4):338–351. doi: 10.1056/NEJMoa1702900
   PubMed Web of Science ®Google Scholar
• Fizazi K, Foulon S, Carles J, et al. PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. [2022 Apr 30];399(10336):1695–1707. doi: 10.1016/S0140-6736(22)00367-1
   PubMed Web of Science ®Google Scholar
• Chi KN, Agarwal N, Bjartell A, et al; TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. [2019 Jul 4];381(1):13–24. doi: 10.1056/NEJMoa1903307
   PubMed Web of Science ®Google Scholar
• Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in Patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. [2021 Jul 10];39(20):2294–2303. doi: 10.1200/JCO.20.03488
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. [2019 Jul 11];381(2):121–131. doi: 10.1056/NEJMoa1903835
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. [2019 Nov 10];37(32):2974–2986. doi: 10.1200/JCO.19.00799
   PubMed Web of Science ®Google Scholar
• Morris MJ, Rathkopf DE, Novotny W, et al. Phase ib study of enzalutamide in combination with docetaxel in men with metastatic castration-resistant prostate cancer. Clin Cancer Res. [2016 Aug 1];22(15):3774–3781. doi: 10.1158/1078-0432.CCR-15-2638
   PubMed Web of Science ®Google Scholar
• Smith MR, Hussain M, Saad F, et al. ARASENS trial investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. [2022 Mar 24];386(12):1132–1142. doi: 10.1056/NEJMoa2119115
   PubMed Web of Science ®Google Scholar
• Mir N, Burke O, Yates S, et al. Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global young international society of geriatric oncology drug review. Ther Adv Med Oncol. [2023 Jan 28];15:17588359221149887. doi: 10.1177/17588359221149887
   Web of Science ®Google Scholar
• Ramsdale E, Mohamed M, Yu V, et al. Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment. Oncology. [2022 Jul 5];27(7):e580–e588. doi: 10.1093/oncolo/oyac053
   PubMedGoogle Scholar
• Turner JP, Shakib S, Bell JS. Is my older cancer patient on too many medications? J Geriatr Oncol. 2017 Mar;8(2):77–81. doi: 10.1016/j.jgo.2016.10.003
   PubMed Web of Science ®Google Scholar
• Marcath LA, Xi J, Hoylman EK, et al. Comparison of nine tools for screening drug-drug interactions of oral oncolytics. J Oncol Pract. 2018 Jun;14(6):e368–e374. doi: 10.1200/JOP.18.00086
   PubMed Web of Science ®Google Scholar
• Henry MC, Riley CM, Hunter I, et al. Synthesis and evaluation of small molecule inhibitors of the androgen receptor N-Terminal domain. ACS Med Chem Lett. [2023 Nov 17];14(12):1800–1806. doi: 10.1021/acsmedchemlett.3c00426
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Giunta EF, Verzoni E, et al. Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing? Ann Oncol. 2023 Sep;34(9):729–731. doi: 10.1016/j.annonc.2023.06.008
   PubMed Web of Science ®Google Scholar
• Bourlon MT, Valdez P, Castro E. Development of PARP inhibitors in advanced prostate cancer. Ther Adv Med Oncol. [2024 Jan 9];16:17588359231221337. doi: 10.1177/17588359231221337
   Web of Science ®Google Scholar
• Shreve JT, Khanani SA, Haddad TC. Artificial intelligence in oncology: Current capabilities, future opportunities, and ethical considerations. Am Soc Clin Oncol Educ Book. 2022 Apr;42(42):1–10. doi: 10.1200/EDBK_350652
   PubMedGoogle Scholar
• Caroli P, Sandler I, Matteucci F, et al. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2035–2044. doi: 10.1007/s00259-018-4067-3
   PubMed Web of Science ®Google Scholar
• Hofman MS, Lawrentschuk N, Francis RJ, et al. proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. [2020 Apr 11];395(10231):1208–1216. doi: 10.1016/S0140-6736(20)30314-7
   PubMed Web of Science ®Google Scholar
• Ayati N, Herrmann K, Fanti S, et al. More accurate imaging is not stage migration: time to move from “hubble” to “webb” in hormone-sensitive prostate cancer. Eur Urol. 2023 Jan;83(1):6–9. doi: 10.1016/j.eururo.2022.10.005
   PubMed Web of Science ®Google Scholar
• Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. [2023 Oct 19];389(16):1453–1465. doi: 10.1056/NEJMoa2303974
   PubMed Web of Science ®Google Scholar
• Armstrong WR, Clark KJ, Smith CP, et al. PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: a single center post-hoc retrospective analysis. J Clin Oncol. 2023;41(16_suppl):5091–5091. doi: 10.1200/JCO.2023.41.16_suppl.5091
   Google Scholar
• Giunta EF, Gasperoni L, Giorgi U. Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer: the sooner the better? Future Oncol. 2024 Feb;20(4):163–166. doi: 10.2217/fon-2023-1019
   PubMed Web of Science ®Google Scholar